ABIN343363
antibody from antibodies-online
Targeting: CXCR4
CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R
Antibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN343363 - Provider product page
- Provider
- antibodies-online
- Proper citation
- Antibodies-Online Cat#ABIN343363, RRID:AB_10788640
- Product name
- anti-Chemokine (C-X-C Motif) Receptor 4 (CXCR4) antibody
- Antibody type
- Polyclonal
- Antigen
- A synthetic peptide corresponding to a sequence at the N-terminal of human CXCR4, different to the related rat sequence by two amino acids.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Storage
- At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time. Reconstitution: 0.2ml of distilled water will yield a concentration of 500ug/ml.
Submitted references Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell.
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
Increased expression of SDF-1/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast.
The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells.
Cloning and characterizing mutated human stromal cell-derived factor-1 (SDF-1): C-terminal alpha-helix of SDF-1alpha plays a critical role in CXCR4 activation and signaling, but not in CXCR4 binding affinity.
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Chen HY, Wang JM, Wang HY, Zhang YX, Liu W, Pan L, Wang WH, Chen SF, Jin WG, Wang L
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2012 Oct;66(7):549-53
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2012 Oct;66(7):549-53
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma.
Lin F, Zheng SE, Shen Z, Tang LN, Chen P, Sun YJ, Zhao H, Yao Y
Medical oncology (Northwood, London, England) 2011 Jun;28(2):649-53
Medical oncology (Northwood, London, England) 2011 Jun;28(2):649-53
Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway.
Wang J, Cai J, Han F, Yang C, Tong Q, Cao T, Wu L, Wang Z
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Aug;21(6):981-7
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2011 Aug;21(6):981-7
Increased expression of SDF-1/CXCR4 is associated with lymph node metastasis of invasive micropapillary carcinoma of the breast.
Liu F, Lang R, Wei J, Fan Y, Cui L, Gu F, Guo X, Pringle GA, Zhang X, Fu L
Histopathology 2009 May;54(6):741-50
Histopathology 2009 May;54(6):741-50
The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells.
Ping YF, Yao XH, Chen JH, Liu H, Chen DL, Zhou XD, Wang JM, Bian XW
Journal of neuro-oncology 2007 Aug;84(1):21-9
Journal of neuro-oncology 2007 Aug;84(1):21-9
Cloning and characterizing mutated human stromal cell-derived factor-1 (SDF-1): C-terminal alpha-helix of SDF-1alpha plays a critical role in CXCR4 activation and signaling, but not in CXCR4 binding affinity.
Tan Y, Du J, Cai S, Li X, Ma W, Guo Z, Chen H, Huang Z, Xiao J, Cai L, Cai S
Experimental hematology 2006 Nov;34(11):1553-62
Experimental hematology 2006 Nov;34(11):1553-62
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract.
Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T
Nature 1998 Jun 11;393(6685):591-4
Nature 1998 Jun 11;393(6685):591-4
No comments: Submit comment
No validations: Submit validation data